Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1206-87-7

Post Buying Request

1206-87-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1206-87-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1206-87-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,2,0 and 6 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1206-87:
(6*1)+(5*2)+(4*0)+(3*6)+(2*8)+(1*7)=57
57 % 10 = 7
So 1206-87-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2O3/c13-8-2-1-3-11-9(8)10(14)12-4-6-15-7-5-12/h1-3,13H,4-7H2

1206-87-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (3-hydroxypyridin-2-yl)-morpholin-4-ylmethanone

1.2 Other means of identification

Product number -
Other names EINECS 214-893-1

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1206-87-7 SDS

1206-87-7Downstream Products

1206-87-7Relevant articles and documents

Novel methanone derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating blindness related diseases containing the same as an active ingredient

-

Paragraph 0118-0120, (2016/10/10)

The present invention relates to novel methanone derivatives, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating retinal diseases. Since the novel methanone derivatives according to the present invention, optical isomers thereof or pharmaceutically acceptable salts thereof have an excellent effect of inhibiting receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the composition comprising the same as an active ingredient can be advantageously used as a pharmaceutical composition for preventing or treating retinal diseases such as retinitis pigmentosa (RP), Leberandprime;s congenital amaurosis (LCA), Stargardts disease, Usher syndrome, choroideremia, rod-cone or cone-rod dystrophy, ciliopathies, a mitochondrial disorder, progressive retinal atrophy, a degenerative retinal disease, age-related macular degeneration (AMD), wet AMD, dry AMD, geographic atrophy, hereditary or acquired maculopathy, a retinal photoreceptor disease, a retinal pigment epithelial disease, diabetic retinopathy, cystic macular edema, uveitis, retinal detachment, traumatic retinal damage, iatrogenic retinal damage, a macular hole, macular capillary ectasia, a ganglion cell disease, an optic nerve disease, glaucoma, optic neuropathy, ischemic retinal disease , retinopathy of prematurity (ROP), retinal vascular occlusion, hereditary macroaneurysm, a retinal vascular disease , an ophthalmovascular disease, degeneration of retinal neuronal cells caused by glaucoma, or ischemic optic neuropathy.COPYRIGHT KIPO 2015

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1206-87-7